[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354070-105":59,"doc-detail-354070-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","crispr-interference-to-inhibit-oncogenes-for-cancer-therapy-comprehensive-review","CRISPR Interference to Inhibit Oncogenes for Cancer Therapy - Comprehensive review","","CRISPR interference (CRISPRi) is a programmable transcriptional repression method derived from nuclease-deficient CRISPR-Cas systems, enabling selective inhibition of oncogene expression without modifying genomic DNA. The review compares CRISPRi with CRISPR-mediated gene knockout, siRNA/miRNA mRNA inhibition, and small-molecule protein inhibitors, highlighting advantages for transcriptionally dysregulated or otherwise undruggable oncogenes. It covers CRISPRi mechanisms, delivery strategies, preclinical oncology applications, in vivo tumor suppression validation, and translational challenges, supporting CRISPRi as a foundation for next-generation gene-regulatory therapeutics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/crispr-interference-to-inhibit-oncogenes-for-cancer-therapy-comprehensive-review/354070/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/crispr-interference-to-inhibit-oncogenes-for-cancer-therapy-comprehensive-review/354070.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CRISPR interference (CRISPRi) and how does it inhibit oncogenes?","Question",{"text":112,"@type":113},"CRISPRi uses nuclease-deficient CRISPR-Cas systems to provide programmable transcriptional repression, selectively blocking oncogene expression without altering genomic DNA.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CRISPRi compare with other oncogene-targeting technologies?",{"text":117,"@type":113},"The review contrasts CRISPRi with CRISPR-mediated gene knockout, siRNA/miRNA-based mRNA inhibition, and small-molecule inhibitors, emphasizing CRISPRi’s advantages for oncogenes that are transcriptionally dysregulated or difficult to drug.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are undruggable oncogenes a challenge for conventional therapies?",{"text":121,"@type":113},"Many high-priority targets lack binding pockets for small molecules or are intracellular and therefore not accessible to large monoclonal antibodies, limiting protein-level intervention effectiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354070,1790439261,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Review  \nCRISPR Interference to Inhibit Oncogenes for Cancer Therapy Bin Guo   \nAcademic Editor: Claudio Mussolino  \nReceived: 30 March 2026  \nRevised: 11 April 2026  \nAccepted: 13 April 2026  \nPublished: 16 April 2026  \nCopyright: © 2026 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA; [bguo@central.uh.edu](bguo@central.uh.edu)  \nAbstract  \nCRISPR interference (CRISPRi), a programmable transcriptional repression technology derived from nuclease-deficient CRISPR-Cas systems, has emerged as a powerful method for selectively inhibiting oncogene expression without altering the genomic DNA. This feature offers a major advantage over other oncogene targeting technologies such as CRISPRmediated gene knockout, mRNA inhibition by siRNA or miRNA, or small-molecule inhibitors of the proteins encoded by the oncogenes, especially in cancers driven by transcriptional dysregulation or otherwise undruggable oncogenes. Here, I present a comprehensive review of CRISPRi mechanisms, delivery strategies, and preclinical applications in oncology (including advances in targeting core oncogenic drivers like MYC and KRAS) . The advantages of CRISPRi as well as in vivo validation of CRISPRi-mediated tumor suppression are discussed. Finally, I outline translational challenges and future directions for incorporating CRISPRi into precision cancer therapies. The accumulated evidence suggests that CRISPRi could become a cornerstone for next-generation gene-regulatory therapeutics.  \nKeywords: CRISPR interference; CRISPR-Cas; CRISPRi; gene silencing; oncogenes; cancer therapy; gene delivery  \n1. Introduction  \nCancer progression is fundamentally driven by gain-of-function mutations or overexpression of oncogenes or loss-of-function mutations in tumor suppressor genes [1–3] . Classic examples include KRAS [4,5], which when mutated keeps cell division signals permanently turned on, and MYC, a transcription factor that, when overexpressed, drives rapid metabolic reprogramming and uncontrolled proliferation in lymphomas and carcinomas [6–8] . Conversely, tumor suppressors like TP53 (the guardian of the genome) or RB1 act as the brakes [9,10] . Their inactivation removes the cell’s ability to repair DNA or undergo apoptosis, allowing damaged cells to survive and expand.  \nThe pharmacological arsenal against the oncogene drivers has relied on small molecule inhibitors and monoclonal antibodies. These have seen remarkable success; for instance, imatinib revolutionized the treatment of chronic myeloid leukemia by targeting the BCRABL fusion protein [11,12], and trastuzumab significantly improved outcomes in HER2-positive breast cancer [13,14] . However, these protein-level interventions face two systemic hurdles. First is the inevitable development of acquired drug resistance, where tumors evolve secondary mutations (such as the T790M gatekeeper mutation in EGFR) that render inhibitors ineffective [15,16] . Second is the persistent challenge of “undruggable” proteins. Many high-priority targets, such as the aforementioned KRAS mutants or the MYC transcription factor, lack deep hydrophobic binding pockets suitable for small molecules, or are intracellular, making them inaccessible to large monoclonal antibodies [17,18] .  \nTo overcome these limitations, gene silencing technologies have emerged as a transformative alternative. By shifting the focus from the finished protein to the nucleic acid level, strategies like RNA interference (RNAi) [19–21] and antisense oligonucleotides (ASOs) [22,23] aim to degrade the messenger RNA (mRNA) before it is translated. This upstream intervention offers a programmable platform to silence virtually any gene, including those previously deemed undruggable, providing a pathway to halt disease pr","cbCaitciUDBRKLM9","https://ap.wps.com/l/cbCaitciUDBRKLM9","pdf",1128763,14,"English","# Introduction\n## Oncogene drivers and limitations of existing therapies\n## Gene silencing approaches: RNAi and ASOs\n## Resistance challenges and rationale for CRISPRi","[{\"question\":\"What is CRISPR interference (CRISPRi) and how does it inhibit oncogenes?\",\"answer\":\"CRISPRi uses nuclease-deficient CRISPR-Cas systems to provide programmable transcriptional repression, selectively blocking oncogene expression without altering genomic DNA.\"},{\"question\":\"How does CRISPRi compare with other oncogene-targeting technologies?\",\"answer\":\"The review contrasts CRISPRi with CRISPR-mediated gene knockout, siRNA/miRNA-based mRNA inhibition, and small-molecule inhibitors, emphasizing CRISPRi’s advantages for oncogenes that are transcriptionally dysregulated or difficult to drug.\"},{\"question\":\"Why are undruggable oncogenes a challenge for conventional therapies?\",\"answer\":\"Many high-priority targets lack binding pockets for small molecules or are intracellular and therefore not accessible to large monoclonal antibodies, limiting protein-level intervention effectiveness.\"}]","CRISPR Interference to Inhibit Oncogenes for Cancer Therapy - Comprehensive review | PDF",1790108706,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2de9b6ac53854902660c188aec5cb0f3.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/530b1522a1f4b68db2376abb3b14cd65.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95aa8d435ddd67d2d17f8bf46e4334cb.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c077f2a134a1173c3f9b59943dc3d137.webp",980,1385]